High expression of CAV1 was significantly correlated with the shorter overall survival (OS) and progression‐free survival (PFS) of MM patients, especially those patients treated with bortezomib (Figure 1B; Figure S1B,C, Supporting Information). Here, CAV1 is linked to Miyoshi myopathy.